Heart failure and reduced ejection fraction Circulatory System
Conditions
Interventions
A group of patients with HFrEF<40% in stage II to IV of NYHA receiving classic HF treatment with dapagliflozin 10 mg/day were compared with a group of patients with the same profile receiving classic
Sponsors
Mouloud Mammeri University of Tizi-Ouzou
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with HFrEF<40% in NYHA stage II to IV, who presented to our department during the recruitment period
Exclusion criteria
Exclusion criteria: Type 1 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Heart failure functional classification assessed using NYHA stage at the first visit 2. Hospitalization rate recorded in our HF hospital registry at the end of the study 3. Ejection fraction (EF) measured by an echocardiogram (ECG) at the first visit, 3 months, and at 7 months (5-8 months) follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mean left ventricular dysfunction (LVd) measured by an echocardiogram (ECG) at the first visit, 3 months, and at 7 months (5-8 months) follow-up 2. Systolic pulmonary pressure (sPAP) measured by an ECG at the first visit, 3 months, and at 7 months (5-8 months) follow-up 3. Mean longitudinal Strain measured by ECG at the first visit, 3 months, and at 7 months (5-8 months) follow-up 4. Urinary tract infection assessed by interrogation (presence of burning urination) and urine strip (Labstix) at each consultation (at the first visit, 3 months, and at 7 months (5-8 months) follow-up) and if necessary cytobacteriological urine examination (in the case of burning urination) | — |
Countries
Algeria
Outcome results
None listed